The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Dysregulation of Histone Acetylation in the APP/PS1 Mouse Model of Alzheimer's Disease
Open accessAbstract
Epigenetic mechanisms such as post-translational histone modifications are increasingly recognized for their contribution to gene activation and silencing in the brain. Histone acetylation in particular has been shown to be important both in hippocampal long-term potentiation (LTP) and memory formation in mice. The involvement of the epigenetic modulation of memory formation has also been proposed in neuropathological models, although up to now no clear-cut connection has been demonstrated between histone modifications and the etiology of Alzheimer's disease (AD). Thus, we have undertaken preclinical studies in the APP/PS1 mouse model of AD to determine whether there are differences in histone acetylation levels during associative memory formation. After fear conditioning training, levels of hippocampal acetylated histone 4 (H4) in APP/PS1 mice were about 50% lower than in wild-type littermates. Interestingly, acute treatment with a histone deacetylase inhibitor, Trichostatin A (TSA), prior to training rescued both acetylated H4 levels and contextual freezing performance to wild-type values. Moreover, TSA rescued CA3-CA1 LTP in slices from APP/PS1 mice. Based on this evidence, we propose the hypothesis that epigenetic mechanisms are involved in the altered synaptic function and memory associated with AD. In this respect, histone deacetylase inhibitors represent a new therapeutic target to effectively counteract disease progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shrestha, S., & Offer, S. M. (2016) · Medical Epigenetics · doi:10.1159/000444713 · Cited by 8,914
The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
Kang, J., Lemaire, H.-G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K.-H., Multhaup, G., Beyreuther, K., & Müller-Hill, B. (1987) · Nature · doi:10.1038/325733a0 · Cited by 4,619
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051 · cited 1×
“Familial forms of AD [4,5] have been linked to mutations in the gene for amyloid-β protein precursor (A β PP) [4] and two other genes, presenilin 1 (PS1) and presenilin 2 (PS2) [6,7].”
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506 · cited 1×
“Such an accumulation can lead to synaptic disruption since high concentrations of A β have been found to inhibit long-term potentiation (LTP), a cellular model of memory [9–14].”
Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning.
Phillips, R. G., & LeDoux, J. E. (1992) · Behavioral Neuroscience · doi:10.1037/0735-7044.106.2.274 · Cited by 3,292
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Bourtchuladze, R., Frenguelli, B., Blendy, J., Cioffi, D., Schutz, G., & Silva, A. J. (1994) · Cell · doi:10.1016/0092-8674(94)90400-6 · Cited by 1,800
Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1
Duff, K., Eckman, C., Zehr, C., Yu, X., Prada, C.-M., Perez-tur, J., Hutton, M., Buee, L., Harigaya, Y., Yager, D., et al. (1996) · Nature · doi:10.1038/383710a0 · Cited by 1,465
Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report
Nicoll, J. A. R., Wilkinson, D., Holmes, C., Steart, P., Markham, H., & Weller, R. O. (2003) · Nature Medicine · doi:10.1038/nm840 · Cited by 1,397 · cited 1×
“Unfortunately, human trials of an A β vaccine had to be terminated because of encephalitic complications in some of the patients [37].”
Recovery of learning and memory is associated with chromatin remodelling
Fischer, A., Sananbenesi, F., Wang, X., Dobbin, M., & Tsai, L.-H. (2007) · Nature · doi:10.1038/nature05772 · Cited by 1,227
Regulation of histone acetylation during memory formation in the hippocampus
Levenson, J. M., O'Riordan, K. J., Brown, K. D., Trinh, M. A., Molfese, D. L., & Sweatt, J. D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402229200 · Cited by 1,131 · cited 3×
“A cursory review of literature reveals that HDAC inhibition can increase both learning and hippocampal LTP in association with a selective increase of histone acetylation [27–30].”
Kim, D., Nguyen, M. D., Dobbin, M. M., Fischer, A., Sananbenesi, F., Rodgers, J. T., Delalle, I., Baur, J. A., Sui, G., Armour, S. M., et al. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601758 · Cited by 1,074
Chromatin Acetylation, Memory, and LTP Are Impaired in CBP+/− Mice
Alarcón, J. M., Malleret, G., Touzani, K., Vronskaya, S., Ishii, S., Kandel, E. R., & Barco, A. (2004) · Neuron · doi:10.1016/j.neuron.2004.05.021 · Cited by 892
Vecsey, C. G., Hawk, J. D., Lattal, K. M., Stein, J. M., Fabian, S. A., Attner, M. A., Cabrera, S. M., McDonough, C. B., Brindle, P. K., Abel, T., et al. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.0296-07.2007 · Cited by 831
CBP Histone Acetyltransferase Activity Is a Critical Component of Memory Consolidation
Korzus, E., Rosenfeld, M. G., & Mayford, M. (2004) · Neuron · doi:10.1016/j.neuron.2004.06.002 · Cited by 823
A Familial Alzheimer's Disease Locus on Chromosome 1
Levy-Lahad, E., Wijsman, E. M., Nemens, E., Anderson, L., Goddard, K. A. B., Weber, J. L., Bird, T. D., & Schellenberg, G. D. (1995) · Science · doi:10.1126/science.7638621 · Cited by 813
Epigenetic mechanisms in memory formation
Levenson, J. M., & Sweatt, J. D. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1604 · Cited by 767 · cited 2×
“Hence, it would not be surprising that deregulation of epigenetic mechanisms might lead to the disruption of memory-associated gene expression and synaptic plasticity [2].”
Crawley, J. N. (1999) · Brain Research · doi:10.1016/s0006-8993(98)01258-x · Cited by 761
Vitolo, O. V., Sant'Angelo, A., Costanzo, V., Battaglia, F., Arancio, O., & Shelanski, M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172504199 · Cited by 534
Self-citationEpigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders
ABEL, T., & ZUKIN, R. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2007.12.002 · Cited by 494
fMRI studies of associative encoding in young and elderly controls and mild Alzheimer's disease
Sperling, R. A. (2003) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.74.1.44 · Cited by 451
Gong, B., Vitolo, O. V., Trinchese, F., Liu, S., Shelanski, M., & Arancio, O. (2004) · Journal of Clinical Investigation · doi:10.1172/jci22831 · Cited by 442 · cited 5×
“Next, we asked whether HDAC inhibition was also capable of ameliorating the associative memory deficit observed in the APP/PS1 mouse [24].”
InfluentialFuso, A., Seminara, L., Cavallaro, R. A., D'Anselmi, F., & Scarpa, S. (2005) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2004.09.007 · Cited by 406
Green, K. N., Steffan, J. S., Martinez-Coria, H., Sun, X., Schreiber, S. S., Thompson, L. M., & LaFerla, F. M. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3203-08.2008 · Cited by 404 · cited 1×
“In fact, Green and colleagues [33] showed that inhibition of class III NAD + - dependent HDACs using vitamin B3 restored cognitive deficits in the triple transgenic AD mice, via a mechanism involving the reduction of Thr231-phosphotau.”
Progressive age‐related development of Alzheimer‐like pathology in APP/PS1 mice
Trinchese, F., Liu, S., Battaglia, F., Walter, S., Mathews, P. M., & Arancio, O. (2004) · Annals of Neurology · doi:10.1002/ana.20101 · Cited by 373
Self-citationBlock of LTP in rat hippocampus in vivo by β-amyloid precursor protein fragments
Cullen, W. K., Suh, Y.-H., Anwyl, R., & Rowan, M. J. (1997) · NeuroReport · doi:10.1097/00001756-199710200-00006 · Cited by 235
In search of general mechanisms for long-lasting plasticity:Aplysia and the hippocampus
Pittenger, C., & Kandel, E. R. (2003) · Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences · doi:10.1098/rstb.2002.1247 · Cited by 172
(1995) · PubMed · Cited by 167
Presenilins and Alzheimer’s disease: biological functions and pathogenic mechanisms
Czech, C., Tremp, G., & Pradier, L. (2000) · Progress in Neurobiology · doi:10.1016/s0301-0082(99)00033-7 · Cited by 158
Amyloid-β Antibody Treatment Leads to Rapid Normalization of Plaque-Induced Neuritic Alterations
Lombardo, J. A., Stern, E. A., McLellan, M. E., Kajdasz, S. T., Hickey, G. A., Bacskai, B. J., & Hyman, B. T. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-34-10879.2003 · Cited by 149
Impairments of long-term potentiation in hippocampal slices of β-amyloid-infused rats
Itoh, A., Akaike, T., Sokabe, M., Nitta, A., Iida, R., Olariu, A., Yamada, K., & Nabeshima, T. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(99)00601-9 · Cited by 129
Frey, U., Krug, M., Brödemann, R., Reymann, K. G., & Matthies, H. (1989) · Neuroscience Letters · doi:10.1016/0304-3940(89)90152-3 · Cited by 102
Rogaev, E. I., Lukiw, W. J., Lavrushina, O., Rogaeva, E. A., & George‐Hyslop, P. S. (1994) · Genomics · doi:10.1006/geno.1994.1393 · Cited by 55
Santangelo, A., Trinchese, F., & Arancio, O. (2003) · Neurochemical Research · doi:10.1023/a:1023251005197 · Cited by 19
Self-citationTakahashi, H., Mercken, M. H., Honda, T., Saito, Y., Murayama, M., Song, S., & Takashima, A. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00966-5 · Cited by 13
Impairment of hippocampal long-term potentiation by Alzheimer amyloid ?-peptides
Chen, Q.-S., Kagan, B. L., Hirakura, Y., & Xie, C.-W. (2000) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(20000401)60:1<65::aid-jnr7>3.0.co;2-q
Cited by
Alzheimer’s disease: pathogenesis, diagnostics, and therapeutics
Tiwari, S., Atluri, V., Kaushik, A., Yndart, A., & Nair, M. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s200490 · Cited by 1,308
Kilgore, M., Miller, C. A., Fass, D. M., Hennig, K. M., Haggarty, S. J., Sweatt, J. D., & Rumbaugh, G. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.197 · Cited by 727
Histone acetylation: molecular mnemonics on the chromatin
Gräff, J., & Tsai, L.-H. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3427 · Cited by 680
Govindarajan, N., Agis-Balboa, R. C., Walter, J., Sananbenesi, F., & Fischer, A. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110080 · Cited by 405
The epigenetics of aging and neurodegeneration
Lardenoije, R., Iatrou, A., Kenis, G., Kompotis, K., Steinbusch, H. W. M., Mastroeni, D., Coleman, P., Lemere, C. A., Hof, P. R., van den Hove, D. L. A., et al. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.05.002 · Cited by 381
Metadata
- Authors
- Francis, Y. I., Fà, M., Ashraf, H., Zhang, H., Staniszewski, A., Latchman, D. S., & Arancio, O.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2009-07-29
- Volume
- 18
- Issue
- 1
- Pages
- 131-139
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1494932082
- Cited by
- 298
- References
- 38
- FWCI
- 10.04
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.